Amicus Therapeutics Inc and ARYA Sciences Acquisition IV Corp to Announce Formation of a Next-Generation Genetic Medicine Company Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst : Just on the manufacturing front, could you give us a little bit more color on your plans for the gene therapy manufacturing as you build that out at Caritas? And would you plan to do Pompe and Fabry gene therapy manufacturing in-house and just your thinking around that? And then also in manufacturing, just what are your latest conversations on CLN3 and CLN6 manufacturing with the FDA and the latest in terms of the potential timing of pivotal study starts here?

Question: Gil Joseph Blum - Needham & Company, LLC, Research Division - Analyst : I would also like to add my congratulations. You briefly touched upon this, but could you maybe give us a bit of an idea of the R&D cost savings that will happen over time for Amicus with this transfer?

Question: Yun Zhong - BTIG, LLC, Research Division - Analyst : Congratulations on the announcement. And just a follow-up question on Amicus' pipeline. Are you able to give a little guidance on when do you think the next program will potentially enter the clinic? And what do you believe will be the most likely program should be the first one to enter the clinic?

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Congrats on the announcements. I want to ask, John, as you're looking forward to your new company, can you comment on the expertise on late-stage development on gene therapy? And also, can you -- I'm curious your thoughts around the pricing around gene therapy as those treatments are going to the commercial stage -- potentially going to commercial stage. What's your thoughts on the pricing around those?